Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under medicare part d

Jinoos Yazdany; R. Adams Dudley; Grace A. Lin; Randi Chen; Chien Wen Tseng

doi:10.1001/jama.2018.7316

Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under medicare part d

Jinoos Yazdany, R. Adams Dudley, Grace A. Lin, Randi Chen, Chien Wen Tseng

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	931-933
Number of pages	3
Journal	JAMA - Journal of the American Medical Association
Volume	320
Issue number	9
DOIs	https://doi.org/10.1001/jama.2018.7316
State	Published - Sep 4 2018
Externally published	Yes

Bibliographical note

Funding Information:
Funding/Support: This study was funded by grant R03HS016772 from the Agency for Healthcare Research and Quality (Dr Tseng), grant NIH/NIAMS P30 AR070155 from the Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases (Dr Yazdany), the Hawaii Medical Services Association Endowed Chair in Health Services and Quality Research at the University of Hawaii (Dr Tseng), and the Russell/Engleman Medical Research Center for Arthritis at the University of California, San Francisco (Dr Yazdany).

Access

10.1001/jama.2018.7316

OpenUrl availability

Full text

Cite this

@article{44835fba2a0d450988803e4e895cfa07,

title = "Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under medicare part d",

author = "Jinoos Yazdany and {Adams Dudley}, R. and Lin, {Grace A.} and Randi Chen and Tseng, {Chien Wen}",

note = "Funding Information: Funding/Support: This study was funded by grant R03HS016772 from the Agency for Healthcare Research and Quality (Dr Tseng), grant NIH/NIAMS P30 AR070155 from the Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases (Dr Yazdany), the Hawaii Medical Services Association Endowed Chair in Health Services and Quality Research at the University of Hawaii (Dr Tseng), and the Russell/Engleman Medical Research Center for Arthritis at the University of California, San Francisco (Dr Yazdany).",

year = "2018",

month = sep,

day = "4",

doi = "10.1001/jama.2018.7316",

language = "English (US)",

volume = "320",

pages = "931--933",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under medicare part d

AU - Yazdany, Jinoos

AU - Adams Dudley, R.

AU - Lin, Grace A.

AU - Chen, Randi

AU - Tseng, Chien Wen

N1 - Funding Information: Funding/Support: This study was funded by grant R03HS016772 from the Agency for Healthcare Research and Quality (Dr Tseng), grant NIH/NIAMS P30 AR070155 from the Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases (Dr Yazdany), the Hawaii Medical Services Association Endowed Chair in Health Services and Quality Research at the University of Hawaii (Dr Tseng), and the Russell/Engleman Medical Research Center for Arthritis at the University of California, San Francisco (Dr Yazdany).

PY - 2018/9/4

Y1 - 2018/9/4

UR - http://www.scopus.com/inward/record.url?scp=85052997580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052997580&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.7316

DO - 10.1001/jama.2018.7316

M3 - Letter

C2 - 30193264

AN - SCOPUS:85052997580

SN - 0098-7484

VL - 320

SP - 931

EP - 933

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 9

ER -

Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under medicare part d

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this